Evidence map›Paper›PMID 41660075›Full record

ArticlePeerJ2026

Admission serum tropomyosin 4 levels predict 1-year functional outcomes in acute ischemic stroke.

Keying Wu, Mingxi Chen, Huan Wang, Yuyi Zhu, Yaqi Chen, Shihong Zhang, Xinyi Leng, Zilong Hao, Deren Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PeerJ, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Keying Wu *Department of Neurology and Center of Cerebrovascular Diseases, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Mingxi Chen *Department of Neurology and Center of Cerebrovascular Diseases, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Huan WangDepartment of Neurology and Center of Cerebrovascular Diseases, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Yuyi ZhuDepartment of Neurology and Center of Cerebrovascular Diseases, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Yaqi ChenDepartment of Neurology and Center of Cerebrovascular Diseases, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Shihong ZhangDepartment of Neurology and Center of Cerebrovascular Diseases, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Xinyi LengDepartment of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong SAR, China.ORCID 0000-0001-7300-6647
Zilong HaoDepartment of Neurology and Center of Cerebrovascular Diseases, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Deren WangDepartment of Neurology and Center of Cerebrovascular Diseases, West China Hospital, Sichuan University, Chengdu, Sichuan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Tropomyosin 4 (TPM4) regulates neurite outgrowth and vascular pathology but its role as a biomarker for predicting outcomes in stroke patients is unclear. This study investigated the association between serum TPM4 levels and 1-year functional outcomes in acute ischemic stroke (AIS) patients. Methods: AIS patients admitted within 24 h post-onset from the Chengdu Stroke Registry were included. Serum TPM4 levels were measured by enzyme-linked immunosorbent assay (ELISA). Poor functional outcomes were defined as a modified Rankin Scale (mRS) score >2 at 1 year after stroke onset. Multivariate logistic regression assessed TPM4's association with outcomes, with its predictive incremental value evaluated by discrimination, reclassification, and overall performance metrics. Results: Among 181 patients (median age 66 years, 64.1% male), 59 (32.6%) experienced poor outcomes at 1 year, including 16 deaths (8.8%). Serum TPM4 levels on admission were negatively correlated with the National Institutes of Health Stroke Scale (NIHSS) score ( Conclusions: Lower serum TPM4 levels on admission were independently associated with poor functional outcomes at 1 year in AIS patients, suggesting that TPM4 may serve as a potential biomarker for long-term outcomes and offer insights into its potential role in stroke pathophysiology. These findings need to be further verified in external cohorts.

Indexed as

Brain IschemiaIschemic StrokeStrokeTropomyosinAgedBiomarkersEnzyme-Linked Immunosorbent AssayFemaleHumansMaleMiddle AgedPredictive Value of TestsPrognosisRegistriesBiomarkersTPM4 protein, humanTropomyosinBiomarkerBiomarker-based prediction modelsIschemic strokePrognostic predictionTropomyosin 4

Identifiers

PMID41660075
PMCPMC12882732

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.